Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Capstar Special Purpose Acquisition Corp. stock logo
CPSR
Capstar Special Purpose Acquisition
$24.32
+0.0%
$8.28
$6.06
$12.23
$838.87M0.07556,189 shs280 shs
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
$47.88
+2.4%
$42.85
$31.42
$58.26
$3.06B1.27474,381 shs391,972 shs
Metsera Inc. stock logo
MTSR
Metsera
$32.91
+9.3%
$27.78
$12.30
$37.99
$3.46BN/A905,940 shs390,293 shs
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$51.34
+3.3%
$49.60
$32.50
$60.60
$3.18B2.26839,465 shs166,462 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Capstar Special Purpose Acquisition Corp. stock logo
CPSR
Capstar Special Purpose Acquisition
-0.18%+0.10%+1.04%+4.47%+272.28%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-1.58%+0.30%-0.28%+29.93%+7.42%
Metsera Inc. stock logo
MTSR
Metsera
+6.09%+12.05%+9.57%+97.25%+3,011,999,900.00%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
-0.34%-1.02%-8.61%+16.75%+43.27%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Capstar Special Purpose Acquisition Corp. stock logo
CPSR
Capstar Special Purpose Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
2.1644 of 5 stars
3.51.00.00.02.72.50.0
Metsera Inc. stock logo
MTSR
Metsera
N/AN/AN/AN/AN/AN/AN/AN/A
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
2.3405 of 5 stars
3.51.00.00.03.32.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Capstar Special Purpose Acquisition Corp. stock logo
CPSR
Capstar Special Purpose Acquisition
0.00
N/AN/AN/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
3.00
Buy$74.5055.61% Upside
Metsera Inc. stock logo
MTSR
Metsera
3.00
Buy$55.0067.12% Upside
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
3.00
Buy$66.1028.74% Upside

Current Analyst Ratings Breakdown

Latest CPSR, PTGX, MLTX, and MTSR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/20/2025
Metsera Inc. stock logo
MTSR
Metsera
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$65.00
6/17/2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$72.00
6/10/2025
Metsera Inc. stock logo
MTSR
Metsera
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$56.00 ➝ $62.00
6/3/2025
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$67.00
6/3/2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00
5/19/2025
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradePeer Perform ➝ Outperform$61.00
5/19/2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
5/13/2025
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$78.00 ➝ $80.00
5/13/2025
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$66.00 ➝ $66.00
4/30/2025
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$66.00 ➝ $66.00
4/10/2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Capstar Special Purpose Acquisition Corp. stock logo
CPSR
Capstar Special Purpose Acquisition
N/AN/AN/AN/A($1.18) per shareN/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
N/AN/AN/AN/A$7.09 per shareN/A
Metsera Inc. stock logo
MTSR
Metsera
N/AN/AN/AN/A($2.46) per shareN/A
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$434.43M7.33$4.65 per share11.04$11.33 per share4.53
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Capstar Special Purpose Acquisition Corp. stock logo
CPSR
Capstar Special Purpose Acquisition
-$15.30MN/A0.00N/AN/AN/AN/AN/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-$118.94M-$2.30N/AN/AN/AN/A-30.81%-28.40%8/6/2025 (Estimated)
Metsera Inc. stock logo
MTSR
Metsera
-$209.13MN/A0.00N/AN/AN/AN/AN/A
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$275.19M$0.7568.32N/AN/A27.04%9.22%8.31%8/5/2025 (Estimated)

Latest CPSR, PTGX, MLTX, and MTSR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q1 2025
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-$0.73N/AN/AN/AN/AN/A
8/5/2025Q2 2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
-$0.53N/AN/AN/A$8.32 millionN/A
5/12/2025Q1 2025
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-$0.76-$0.63+$0.13-$0.63N/AN/A
5/12/2025Q1 2025
Metsera Inc. stock logo
MTSR
Metsera
N/A-$1.03N/A-$1.03N/AN/A
5/6/2025Q1 2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
-$0.50-$0.19+$0.31-$0.19$30.44 million$28.32 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Capstar Special Purpose Acquisition Corp. stock logo
CPSR
Capstar Special Purpose Acquisition
N/AN/AN/AN/AN/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
N/AN/AN/AN/AN/A
Metsera Inc. stock logo
MTSR
Metsera
N/AN/AN/AN/AN/A
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Capstar Special Purpose Acquisition Corp. stock logo
CPSR
Capstar Special Purpose Acquisition
N/A
0.13
0.13
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
0.18
21.11
21.11
Metsera Inc. stock logo
MTSR
Metsera
N/A
6.55
6.55
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
N/A
17.25
17.26
CompanyEmployeesShares OutstandingFree FloatOptionable
Capstar Special Purpose Acquisition Corp. stock logo
CPSR
Capstar Special Purpose Acquisition
234.50 millionN/ANot Optionable
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
264.01 million56.30 millionOptionable
Metsera Inc. stock logo
MTSR
Metsera
81105.06 millionN/AN/A
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
12061.98 million58.95 millionOptionable

Recent News About These Companies

PTGX Protagonist Therapeutics, Inc. - Seeking Alpha

New MarketBeat Followers Over Time

Media Sentiment Over Time

Capstar Special Purpose Acquisition stock logo

Capstar Special Purpose Acquisition NYSE:CPSR

Capstar Special Purpose Acquisition Corp. is a blank check company. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to focus on businesses in the consumer, healthcare, and technology, media and telecommunications industries. The company was incorporated in 2020 and is based Austin, Texas.

MoonLake Immunotherapeutics stock logo

MoonLake Immunotherapeutics NASDAQ:MLTX

$47.88 +1.13 (+2.41%)
As of 12:19 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Metsera stock logo

Metsera NASDAQ:MTSR

$32.91 +2.79 (+9.26%)
As of 12:03 PM Eastern

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.

Protagonist Therapeutics stock logo

Protagonist Therapeutics NASDAQ:PTGX

$51.34 +1.64 (+3.31%)
As of 12:19 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.